Trial Profile
To evaluate the efficacy and remission at week 54 of Vedolizumab in inflammatory bowel disease (IBD) in a multicenter cohort of patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2017
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- 06 Apr 2017 New trial record
- 29 Mar 2017 Results published in the Digestive Diseases and Sciences